This work was supported by the Austrian Science Fund FWF (P25015-B13) to T.N. Hartmann and W1213 (ICA PhD program), the “SCRI-LIMCR GmbH” and the province of Salzburg.
TRANSPLANTATION AND CELLULAR ENGINEERING
The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by “on-demand” addition of plerixafor to granulocyte–colony-stimulating factor
Article first published online: 28 MAR 2014
© 2014 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Volume 54, Issue 9, pages 2325–2335, September 2014
How to Cite
Girbl, T., Lunzer, V., Greil, R., Namberger, K. and Hartmann, T. N. (2014), The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by “on-demand” addition of plerixafor to granulocyte–colony-stimulating factor. Transfusion, 54: 2325–2335. doi: 10.1111/trf.12632
- Issue published online: 11 SEP 2014
- Article first published online: 28 MAR 2014
- Manuscript Accepted: 27 JAN 2014
- Manuscript Revised: 24 JAN 2014
- Manuscript Received: 12 NOV 2013
- Austrian Science Fund FWF. Grant Numbers: P25015-B13, W1213
- SCRI-LIMCR GmbH
Granulocyte–colony-stimulating factor (G-CSF) is routinely used for mobilization of hematopoietic stem and progenitor cells preceding autologous transplantation after high-dose chemotherapy in hematologic malignancies. However, due to high mobilization failure rates, alternative mobilization strategies are required.
Study Design and Methods
Patients who poorly mobilized CD34+ hematopoietic cells (HCs) with G-CSF additionally received the CXCR4 antagonist plerixafor. The phenotype of CD34+ HCs collected after this plerixafor-induced “rescue” mobilization, in regard to adhesion molecule and CD133, CD34, and CD38 expression in comparison to CD34+ HCs collected after traditional G-CSF administration in good mobilizers, was analyzed flow cytometrically. To confirm previous studies in our patient cohort, the efficiency of mobilization and subsequent engraftment after this “on-demand” plerixafor mobilization were analyzed.
Pronounced mobilization occurred after plerixafor administration in poor mobilizers, resulting in similar CD34+ cell yields as obtained by G-CSF in good mobilizers, whereby plerixafor increased the content of primitive CD133+/CD34+/CD38– cells. The surface expression profiles of the marrow homing and retention receptors CXCR4, VLA-4, LFA-1, and CD44 on mobilized CD34+ cells and hematopoietic recovery after transplantation were similar in patients receiving G-CSF plus plerixafor or G-CSF. Unexpectedly, the expression levels of respective adhesion receptors were not related to mobilization efficiency or engraftment.
The results show that CD34+ HCs collected by plerixafor-induced rescue mobilization are qualitatively equivalent to CD34+ HCs collected after traditional G-CSF mobilization in good mobilizers, in regard to their adhesive phenotype and engraftment potential. Thereby, plerixafor facilitates the treatment of poor mobilizers with autologous HC transplantation after high-dose chemotherapy.